MR-146NCT07923045
A Phase 1/2 Clinical Trial to Evaluate the Safety and Efficacy of MR-146 in Subjects With Stage I and Stage II Neurotrophic Keratopathy
At risk: Primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary endpoint(s) modified
- Study sites: 11 to 12
- Study title shortened, about 19 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Incidence of Dose-Limiting Toxicities (Safety)
Timeframe: Week 52
Incidence of serious adverse events (Safety)
Timeframe: Week 52
Incidence of adverse events (Safety)
Timeframe: Week 52
Arms and interventions
MR-146 (Low)Experimental
Participants will receive a single low dose of MR-146 administered via an intralacrimal gland injection
MR-146 (mid)Experimental
participants will receive a single mid-level dose of MR-146 administered via an intralacrimal gland injection
MR-146 (high)Experimental
participants will receive a single high dose of MR-146 administered via an intralacrimal gland injection
Genetic: MR-146
Sites
12 sites in 1 country